Iacta, Tallc announce collaboration to employ novel drug delivery technology
Click Here to Manage Email Alerts
Iacta Pharmaceuticals and Tallc will enter into a strategic collaboration and licensing agreement to implement Tallc’s SmartCelle technology in clinical development, according to a press release from the companies.
Through the agreement, Iacta gains the use of Tallc’s proprietary SmartCelle micellar technology, a platform for panocular drug delivery. Iacta intends to use the technology to deliver at lease one new ophthalmic therapeutic, according to the release.
“Iacta was formed with the mission of developing and commercializing innovative ocular therapies through novel compounds and utilizing leading drug delivery technologies, and we view this collaboration as the perfect synergy to realize the full potential of our ophthalmology pipeline,” Damon Burrows, CEO of Iacta, said in the release. “We are excited to explore how best to deploy the SmartCelle technology within our current pipeline, as well as the future co-development opportunities this partnership provides.”
Additionally, the collaboration gives Iacta “exclusive rights to negotiate a separate license agreement for the right to co-develop Tallc’s lead product candidate TA-A001, a novel anti-inflammatory anti-angiogenic molecule with analgesic properties in various disease state models.”
Financial terms of the deal were not disclosed.
Read more about
Click Here to Manage Email Alerts